ClinicalTrials.gg
Sign In
RecruitingNCT03539133SYSTEMIUpdated Jan 22, 2026

Systemic Organ Communication in STEMI

An observational study in ST-segment Elevation Myocardial Infarction (STEMI), sponsored by Heinrich-Heine University, Duesseldorf. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-22.

Sponsored by Heinrich-Heine University, Duesseldorf · Observational

From the registry’s dates

  • Started Oct 2017; still recruiting 9 years later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,000
Ages
18 Years and older
Sex
All
01

Study summary

Despite progress in pre-hospital care, ambulance logistics, pharmacotherapy and PPCI techniques, ST-segment elevation myocardial infarction (STEMI) continues to confer a substantial burden of morbidity and mortality.

Within the STEMI population, there is a spectrum of higher and lower risk patients. The aim of this cohort study is to collect prospectively and systematically clinical research data from STEMI patients. This cohort study is an open-end observational study to identify master switches in myocardial ischemia.

02

Conditions studied

  • ST-segment Elevation Myocardial Infarction (STEMI)

Keywords

  • STEMI
  • infarction
  • coronary artery disease
  • comorbidities
  • diabetes
  • anemia
03

In context

ST Elevation Myocardial Infarction

850 studies on the registry are indexed under ST Elevation Myocardial Infarction; 197 are open to participants now.

This study's planned enrollment of 1,000 is above the median of 335 across 297 observational studies indexed under ST Elevation Myocardial Infarction.

Browse ST Elevation Myocardial Infarction studies →

Lead sponsor

Heinrich-Heine University, Duesseldorf is the lead sponsor of 180 studies on the registry; 54 are open to participants now.

Browse Heinrich-Heine University, Duesseldorf studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients suffering from STEMI

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients suffering from STEMI

Exclusion criteria

Exclusion Criteria:

  • \< 18 years
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Interventions

  • Othercollection of clinical data

    prospectively and systematically collection of clinical research data from STEMI patients

06

What researchers measure

Primary outcomes

  1. Left-ventricular function

    * LV-EF \< 40% at 6 months * Δ LV-EF ≥ 5% between day 5 of hospitalization and 6 months

    Time frame: 6 months

  2. Left-ventricular remodeling

    Δ LVEDV ≥ 20% or Δ LVESV ≥ 15% between day 5 of hospitalization and 6 months

    Time frame: 6 months

  3. Myocardial texture

    * Infarct/Scar size \> 17.9% or MVO (yes) or IMH (yes) on day 5 of hospitalization or at 6 months * remote zone ΔECV between day 5 of hospitalization and 6 months

    Time frame: on day 5 of hospitalization and 6 months

  4. Patency rate

    Coronary patency rate

    Time frame: 6 months

Secondary outcomes

  1. All cause mortaltiy

    All cause mortaltiy

    Time frame: 12 months

  2. MACCE

    cardiovascular death, non-fatal stroke or myocardial infarction

    Time frame: 12 months

  3. Re-Hospitalisation due to heart failure

    Re-Hospitalisation due to heart failure

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Helten C, Benkhoff M, Mourikis P, Metzen D, Barcik M, Hu H, Ayhan A, Haurand J, Alde K, Duse D, Jung C, Hohlfeld T, Levkau B, Petzold T, Borst O, Becher S, Ommer-Blaesius M, Witkowski S, Lang A, Cramer M, Dannenberg L, Kelm M, Gerdes N, Polzin A. Acetylsalicylic acid improves outcome after acute myocardial infarction by reducing thromboinflammation. J Thromb Haemost. 2026 Jun;24(6):2273-2292. doi: 10.1016/j.jtha.2026.02.003. Epub 2026 Mar 4. PubMed 41791655 ↗
  • Benkhoff M, Alde K, Ehreiser V, Dahlmanns J, Metzen D, Haurand JM, Duse DA, Jung C, Kelm M, Petzold T, Polzin A. Thromboinflammation is associated with clinical outcome after ST-elevation myocardial infarction. Blood Adv. 2024 Nov 12;8(21):5581-5589. doi: 10.1182/bloodadvances.2024014273. PubMed 39226457 ↗
  • Bonner F, Jung C, Polzin A, Erkens R, Dannenberg L, Ipek R, Kaldirim M, Cramer M, Wischmann P, Zaharia OP, Meyer C, Flogel U, Levkau B, Godecke A, Fischer J, Klocker N, Kruger M, Roden M, Kelm M. SYSTEMI - systemic organ communication in STEMI: design and rationale of a cohort study of patients with ST-segment elevation myocardial infarction. BMC Cardiovasc Disord. 2023 May 3;23(1):232. doi: 10.1186/s12872-023-03210-1. PubMed 37138228 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03539133
Lead sponsor
Heinrich-Heine University, Duesseldorf
Responsible party
Sponsor
First posted
May 29, 2018
Start date
Oct 18, 2017
Primary completion
Jun 2030 (estimated)
Completion
Jun 2030 (estimated)
Last update
Jan 22, 2026

Study contacts

Christian Jung, MD, PhD
Contact
christian.jung@med.uni-duesseldorf.de
+492118118800
Florian Bönner, MD,
Contact
florian.boenner@med.uni-duesseldorf.de
+492118118800
Christian Jung, MD, PhD
principal investigator · Division of Cardiology, Pulmonary Disease and Vascular Medicine
Malte Kelm, MD
study chair · Division of Cardiology, Pulmonary Disease and Vascular Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

ST Elevation Myocardial Infarction →

Other studies from this sponsor

Heinrich-Heine University, Duesseldorf →

Start the discussion